discovery unity


Accelerating R&D and laying the foundation of Digital Precision Medicine
in Pharma & Life Sciences

Data Collection

Discovery UNITY is a multimodality platform that supports multiple types of images and formats.

Compatible formats today (continuously expanding):

  • Industry standard DICOM,
  • Device-Specific formats
  • and non-medical images (PNG, JEPG, TIFF, PDF).

Image types supported today (continuously expanding):

  • OCT (cube, cross, radial, line)
  • Fundus
  • Color Fundus

Data processing & visualization

  • First, data is organized, harmonized and aggregated into a single ecosystem.
  • Then data is analysed at scale using artificial intelligence to extract insights about disease progression, treatment outcomes and patient progression prediction.

Data Collaboration

Participative research is enabled across the organization and with external experts globally using secure, cloud-based access to data anytime from anywhere, with insights from both certified and validated research modules for analysis.

Discovery UNITY is an organization’s:

Single data platform to manage data from different sources and devices, at scale. Access data anytime from anywhere.

Integrated AI technology to extract insights across datasets for a better understanding of diseases and patient groups.

A data insurance policy. Secured storage and archival only accessible to authorized personnel to provide peace-of-mind to an organization’s precious resource, its data.

Use case:
Accelerate Pharma R&D Pipeline

INCREASED TIME & RISK: pharma pipelines from discovery to launch can take an average of 10-12 years, at an average cost of $2.6B. Significant risk is undertaken as only an average of 1 compound out of 10,000 is introduced to the market.
COMPETITION FOR PATIENT POPULATIONS: Therapies targeting similar pathways limit the market potential and the opportunity to personalize therapy with more well-defined assessment criteria.


R&D pipeline time and costs can be reduced by leveraging Discovery UNITY features:
- clinical research workflows (grading surveys and feedback collection for collaborative and independent data review)
- multimodal data management analysis
- AI models for analysis in wet and dry AMD, Diabetic Retinopathy and Macular Edema, Retinal Vein Occlusion, Geographic Atrophy and Glaucoma.


From a standard analysis workflow of 6 months to 6 weeks  reduction of both time and cost of research workflows for a study of >15,000 OCTs

Interested in learning more?


RetinAI Discovery is a CE-marked medical device according to the Medical Devices Regulation (EU) 2017/745
and the AI models are CE-marked devices according to Medical Devices Directive 93/42/EEC
RetinAI Discovery® is a 510(k) FDA Cleared medical device in US.
RetinAI Discovery® and Retinai® are both trademarks of RetinAI Medical AG.

The AI modules for biomarkers, fluid and layer segmentation and quantification
in retinal pathologies are for research use only in the USA.
The Advanced Segmentation and GA modules are for research use only.
Please be advised these tools are not intended to be a substitute for medical advice, diagnosis or treatment.
We do not warrant any reliance on the accuracy, completeness or usefulness of any content.